Clinical trials sponsored by Eli Lilly and Company

Phase breakdown

Conditions studied

Recruiting trials led by Eli Lilly and Company

• A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
  NCT07641517 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · 37 locations
• A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
  NCT06297590 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 10 locations
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
  NCT04844606 · Phase: Phase 3 · Ages: 2 Years to 19 Years · Sex: All (male and female) · 136 locations
• A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
  NCT07483073 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 140 locations
• A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
  NCT05986292 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 56 locations
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 563 locations
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · 117 locations
• A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
  NCT06566170 · Phase: Not specified · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
  NCT07286175 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 87 locations
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder
  NCT07412756 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 179 locations
• A Study of Brenipatide in Adult Participants With Schizophrenia
  NCT07410507 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 103 locations
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · 59 locations
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
  NCT07589595 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female) · 72 locations
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
  NCT07738614 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 157 locations
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 324 locations
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
  NCT07369011 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 115 locations
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 374 locations
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
  NCT06598943 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 207 locations
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  NCT06119581 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 418 locations
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 89 locations
• A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
  NCT05307705 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 50 locations
• A Study of LY3439539 in Participants With Alzheimer's Disease
  NCT07598370 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 11 locations
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 60 locations
• A Study of LY3971297 in Participants With Heart Failure
  NCT07547540 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 12 locations
• A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
  NCT06657768 · Phase: Phase 1 · Ages: 45 Years to 85 Years · Sex: All (male and female) · 13 locations
• A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
  NCT06809400 · Phase: Phase 1 · Ages: 30 Years to 85 Years · Sex: All (male and female) · 14 locations
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
  NCT06561685 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
  NCT06400472 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• A Study of LY4175408 in Participants With Advanced Cancer
  NCT07046923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
  NCT07258849 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
  NCT07100119 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 12 locations
• A Study of LY4257496 in Participants With Cancer (OMNIRAY)
  NCT07114601 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
• A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
  NCT07276958 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 9 locations
• A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
  NCT07213791 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
  NCT07483099 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 70 locations
• A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
  NCT07215559 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 42 locations
• A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
  NCT05509777 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 81 locations
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
  NCT06672939 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 34 locations
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
  NCT07153471 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
  NCT07613307 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 40 locations
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
  NCT07241390 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 566 locations
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
  NCT07202884 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · 136 locations
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 359 locations
• A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
  NCT06439277 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 69 locations
• A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
  NCT07219173 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 121 locations
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 55 locations
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
  NCT07589608 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 40 locations
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
  NCT07571161 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · 30 locations
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
  NCT07353931 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 152 locations
• Epidemiology and Biomarker Study in Alzheimer's Disease
  NCT07142954 · Phase: Phase 3 · Ages: 55 Years to 75 Years · Sex: All (male and female) · 4 locations
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
  NCT05768139 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 65 locations
• LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
  NCT07186101 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 147 locations
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
  NCT07415044 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 259 locations
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06586515 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 374 locations
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 183 locations

Common questions

How many trials is Eli Lilly and Company recruiting for?

Eli Lilly and Company is the lead sponsor of 60 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.